Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Immunome, Inc.
  6. News
  7. Summary
    IMNM   US45257U1088

IMMUNOME, INC.

(IMNM)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immunome : Corporate Presentation

09/21/2021 | 10:42am EDT

Harnessing the Human

Memory B Cell Response

To Develop Antibody-

Based Therapeutics

September 21, 2021

Immunome, Inc.

665 Stockton Drive, Suite 300 | Exton, PA 19341 610.321.3700 | www.immunome.com

Copyright © 2021 Immunome, Inc. All rights reserved.

Disclaimers and Forward-Looking Statements

This presentation includes certain disclosures that contain "forward-looking statements" intended to qualify for the "safe harbor" from liability established by the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding our beliefs and expectations regarding the advancement of our oncology and COVID-19 therapeutic antibody programs, execution of our regulatory, clinical and strategic plans, anticipated upcoming milestones for IMM-BCP-01 and IMM-ONC-01, including expectations regarding therapeutic potential and benefits thereof, and IND filings. Forward-looking statements may be identified by the words "anticipate," believe," "estimate," "expect," "intend," "plan," "project," "may," "will," "could," "should," "seek," "potential" and similar expressions. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, those risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business, operations, strategy, goals and anticipated milestones; our ability to execute on our strategy with respect to our R&D efforts, IND submissions and other regulatory filings, timing of these filings and governmental authority feedback regarding the same, initiation of clinical studies, generation of clinical data and other anticipated milestones as and when anticipated; the effectiveness of our product candidates, including the possibility that further preclinical data and any clinical trial data may be inconsistent with the data used for advancing the product candidates; our ability to fund operations; our reliance on vendors; the competitive landscape; and the additional risks and uncertainties set forth more fully under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (SEC) on March 25, 2021, and elsewhere in our filings and reports with the SEC. Forward-looking statements contained in this document are made as of this date, and we undertake no duty to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable law.

This document may contain product names, trade names, trademarks and service marks of the Company and of other organizations, of which are the properties of their respective owners.

Statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of

the date of this presentation, including independent market research, industry publications and surveys, governmental agencies and publicly available information. While we believe that information provides a reasonable basis for these statements, it may be limited or incomplete and we may have not independently verified it. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review or verification of, all relevant information.

We may make statements about estimated dates for milestones related to our programs. Estimates involve risks and uncertainties and are subject to change based on various factors and evolution over time.

In this presentation and oral commentary, we may discuss our current and potential future product candidates that have not yet undergone clinical trials or been approved for marketing by the U.S. Food and Drug Administration or other governmental authority. No representation is made as to the safety or effectiveness of these current or potential future product candidates for the use for which such product candidates are being studied. This presentation does not constitute an offering of securities of any kind.

2

Experienced Management Team

Purnanand Sarma, PhD

Former CEO of Taris Biomedical

President & CEO

Sold to Johnson & Johnson in 2019

Corleen Roche

Former US CFO Biogen

Chief Financial Officer

Former CFO, Global Vaccines, Wyeth/Pfizer

Dennis Giesing, PhD

Former CSO at Taris Biomedical

Led BARDA funded pandemic flu program at MediVector

Chief Development Officer

Sandra Stoneman, Esq.

Former Partner at Duane Morris

Chief Legal Officer

Life Sciences practice group leader

Mike Morin, PhD

Oversaw cancer, immunology and anti-bacterial

Chief Scientist

drug discovery at Pfizer

Matthew Robinson, PhD

Antibody Structure Function Expert

SVP, Research & Development

formerly at Fox Chase Cancer Center

3

Copyright © 2021 Immunome, Inc. All rights reserved.

Immunome

"At A Glance"

Proprietary Discovery Engine

Rapid, Unbiased Interrogation of Patient Memory B Cells

Applicable Across Multiple Therapeutic Areas

ADVANCING CLINICAL PROGRAMS

IMM-BCP-01 Treatment of COVID-19

  • Three antibody cocktail
  • Binds to three non-overlapping regions of the spike protein
  • ACE2 and Non ACE2 dependent neutralization
  • Potent Effector Function - potential for viral clearance

IMM-ONC-01 Treatment of Solid Tumors: Targeting IL-38

  • Reverses IL-38 induced dampening of anti-tumor immunity
  • IL38 is a novel innate immune checkpoint
  • Potential indications include Lung, Head & Neck, Melanoma

ROBUST PIPELINE

  • Multiple target rich areas of cancer biology
    • Membrane Dynamics/Exosomes
    • Antibody Drug Conjugates (ADCs)
  • Anti-infectives
    • Rapid Response to new infections/outbreaks

IND Submission Q4 2021 Topline Data H1 2022

IND submission Q1 2022

Potential for multiple new programs and partnerships

Copyright © 2021 Immunome, Inc. All rights reserved.

4

Immunome Development Pipeline and Anticipated Key Milestones

ANTI-INFECTIVES

TARGET

PRODUCT CANDIDATE

DISCOVERY

PRECLINICAL

ANTICIPATED

DESCRIPTION

MILESTONE

IMM-BCP-01

Three SARS-

Three antibody

IND filing Q4 2021

CoV-2 Epitopes

cocktail

ONCOLOGY

TARGET

PRODUCT CANDIDATE

DISCOVERY

PRECLINICAL

ANTICIPATED

DESCRIPTION

MILESTONE

IMM-ONC-01

IL-38

Anti IL-38 antibody

IND filing Q1 2022

Copyright © 2021 Immunome, Inc. All rights reserved.

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Immunome Inc. published this content on 21 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 September 2021 14:41:02 UTC.


ę Publicnow 2021
All news about IMMUNOME, INC.
10/25IMMUNOME : Corporate Presentation
PU
10/20IMMUNOME : Announces Submission for Publication of Pre-clinical Research Detailing the Imp..
BU
10/20Immunome, Inc. Announces Submission for Publication of Pre-Clinical Research Detailing ..
CI
10/19IMMUNOME : Corporate Presentation
PU
10/18IMMUNOME INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
10/07IMMUNOME : Presents Compelling Preclinical Data on Anti-IL-38 Antibody Program at the Amer..
BU
09/30IMMUNOME : to Present Preclinical Data on Anti IL-38 Antibody Program at the American Asso..
BU
09/22IMMUNOME : to Present at the Cantor Global Healthcare Conference
BU
09/21IMMUNOME : Corporate Presentation
PU
09/21IMMUNOME INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
More news
Analyst Recommendations on IMMUNOME, INC.
More recommendations
Financials (USD)
Sales 2021 11,2 M - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -12,0x
Yield 2021 -
Capitalization 273 M 273 M -
Capi. / Sales 2021 24,5x
Capi. / Sales 2022 -
Nbr of Employees 23
Free-Float 72,7%
Chart IMMUNOME, INC.
Duration : Period :
Immunome, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUNOME, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 22,60 $
Average target price 21,00 $
Spread / Average Target -7,08%
EPS Revisions
Managers and Directors
Purnanand D. Sarma President, Chief Executive Officer & Director
Corleen M. Roche Chief Financial Officer
Michael Rapoport Chairman
Matthew K. Robinson Senior Vice President-Research & Development
John L. LaMattina Independent Director
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOME, INC.133.47%234
GILEAD SCIENCES, INC.14.61%84 921
BIONTECH SE241.97%70 618
WUXI APPTEC CO., LTD.20.76%64 231
REGENERON PHARMACEUTICALS22.04%61 565
VERTEX PHARMACEUTICALS-23.44%47 753